The compound CC-220 is currently in phase III clinical trials for the treatment of systemic lupus erythematosus and relapsed/refractory multiple myeloma, through the induction of IKZF1 and IKZF3 protein degradation213. This evidence concerns the gene IKZF1 and plasma cell myeloma.